Global Call to Action to scale-up coverage of intermittent preventive treatment of malaria in pregnancy: seminar report. by Agarwal, Koki et al.
Agarwal, K; Alonso, P; Chico, RM; Coleman, J; Dellicour, S; Hill,
J; Majeres-Lugand, M; Mangiaterra, V; Menendez, C; Mitchell, K;
Roman, E; Sicuri, E; Tagbor, H; van Eijk, AM; Webster, J (2015)
Global Call to Action to scale-up coverage of intermittent preventive
treatment of malaria in pregnancy: seminar report. Malar J, 14 (1).
p. 206. ISSN 1475-2875 DOI: 10.1186/s12936-015-0730-3
Downloaded from: http://researchonline.lshtm.ac.uk/2172792/
DOI: 10.1186/s12936-015-0730-3
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
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intermittent preventive treatment of malaria in
pregnancy: seminar report
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Abstract
In 2014, a global ‘Call to Action’ seminar for the scale-up of intermittent preventive treatment of malaria in pregnancy
was held during the 63rd Annual Meeting of the American Society of Tropical Medicine and Hygiene. This report
summarizes the presentations and main discussion points from the meeting.
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Purpose of the meeting
On the 5th of November 2014, during the 63rd Annual
Meeting of the American Society of Tropical Medicine
and Hygiene in New Orleans, USA, the Roll Back Mal-
aria (RBM) partnership Malaria in Pregnancy (MiP)
Working Group and the Malaria in Pregnancy Consor-
tium (MiPc), with support from Medicines for Malaria
Venture and the London School of Hygiene and Trop-
ical Medicine (LSHTM), hosted a global ‘Call to Action’
seminar for the scale-up of intermittent preventive treat-
ment of malaria in pregnancy (IPTp) (see seminar
agenda in Additional file 1). The meeting was attended
by 80 representatives from 37 institutions across 15
countries, nine of which were sub-Saharan, including
policymakers, programme managers, researchers, tech-
nical advisors and donors.
Administration of IPTp with sulphadoxine-pyrimeth-
amine (SP) as part of routine antenatal care (ANC) is one
of three key interventions recommended by the World
Health Organization (WHO) for the control of malaria in
pregnancy in areas of stable malaria transmission. The
other two interventions are the provision of insecticide-
treated nets and effective case management. Coverage has
remained unacceptably low in countries with an IPTp
policy. The aim of this seminar was to convene key stake-
holders to review barriers to the scale-up of IPTp and to
develop an action plan to increase coverage rapidly. This
report summarizes central issues presented and discussed
during the Call to Action seminar relating to the scale-up
of IPTp. Key issues raised at the seminar have been used
to outline a set of recommended actions as part of a Glo-
bal Call to Action which aims to increase national and
international coverage to rapid effect.
Pedro Alonso, the newly appointed Director of the
WHO Global Malaria Programme (GMP), strongly
voiced his support for increasing the coverage of IPTp
and pledged that he would make the scale-up of IPTp a
priority for GMP. Reinforcing this point, he said that
until better and more cost-effective tools are available
for the prevention of malaria in pregnancy, GMP will
drive the scale-up for IPTp coverage.
“Intermittent preventive therapy for pregnancy is a
life-saving tool which will be a main priority for the
WHO Global Malaria Programme team moving for-
ward.” (Pedro Alonso, Director of the Global Malaria
Programme, World Health Organization)
Status of IPTp coverage in sub-Saharan Africa
Current coverage estimates of IPTp and insecticide-
treated nets (ITNs) in sub-Saharan Africa were presented
by Anna Maria van Eijk (Liverpool School of Tropical
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Medicine, UK) for the period between 2003 and 2014
based on previously published data [1, 2], highlighting
an alarming lack of IPTp scale-up. Although coverage
for IPTp increased from less than 5 % in 2003 to above
20 % in 2010, no further progress has been made with
average coverage rates that have since stagnated
between 22 % and 24 %. Overall, IPTp coverage esti-
mates remain far below global targets set by the RBM
Partnership of 80 % by 2010, and 100 % (universal
coverage) by 2015. Although six countries (The
Gambia, Ghana, Malawi, Sao Tomé and Principe,
Senegal and Zambia) reached the original 60 % cover-
age target for 2005, the combined estimate for all coun-
tries with an IPTp policy was 24 % in 2013 (Fig. 1). It is
of particular concern that the latest estimates for 2014
indicate that coverage is falling in some countries. Pro-
gress for ITN coverage is comparatively better but still
unacceptably low at 38 % overall. Production of ‘rolling
coverage estimates’ are essential to track overall pro-
gress as well as to estimate the uptake and impact of
the revised WHO recommendation for IPTp [3]. WHO
updated the IPTp policy recommendation in September
2012, increasing the regimen from at least two doses of
SP to the provision of a dose of IPTp-SP given at every
ANC visit beginning as early as possible in the 2nd tri-
mester throughout pregnancy and at least one month
apart, ideally administered as directly observed therapy
[3]. Measuring the impact of the policy update will re-
quire national household surveys to include data on
two, three, and more than three doses of IPTp.
Factors affecting antenatal care delivery of IPTp
Examples from observational studies in Mali and Kenya
presented by Jayne Webster (LSHTM, UK) showed that
IPTp delivered by direct observation at antenatal care
(ANC) facilities was low and ineffective. Despite differ-
ent operating contexts across countries in terms of IPTp
policy on timing of doses and HIV prevalence, the same
intermediate steps appeared to impede receiving any SP,
and receiving SP by direct observation. SP stock-outs
were not an issue when surveys were conducted. Inter-
estingly, surveys revealed high variability across health
facilities within the same district and highlighted the
need to monitor and to intervene at the facility level to
overcome barriers to IPTp, as well as to make distinc-
tions between issues that are driven by individual pro-
viders and, separately, those related to facilities. Surveys
employed mixed-methods to identify ineffective pro-
cesses and their predictors for the delivery of IPTp with
qualitative analysis offering deeper insights into certain
practices as summarized in Table 1. These surveys en-
abled an in-depth assessment of the ANC processes that
are required to deliver IPTp as well as to quantify the
major barriers to its provision. Moreover, evidence from
mixed-methods is needed to inform policymakers and
programme managers on the most appropriate interven-
tions that can improve the uptake of IPTp as well as
other ANC interventions.
Harry Tagbor (Kwame Nkrumah University of Science
and Technology, Ghana) presented encouraging progress
in IPTp uptake in Ghana between 2003 and 2008. National
Fig. 1 IPTp coverage in sub-Saharan Africa between 2003 and 2014
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coverage was below 5 % in 2003 and rose to 44 % in 2008,
although with marked variation between regions (see
Fig. 2). A study from the rural district of Ashanti in 2009
found over 80 % of pregnant women to have received at
least two doses of IPTp while 71 % of women made more
than four ANC visits during their pregnancies. The
number of ANC visits was significantly associated with
greater IPTp dosing. This study further highlighted the
importance of making every ANC visit count as an oppor-
tunity to deliver IPTp, and also the need to address bottle-
necks at the local district and health facility levels.
The need for improved communication and messaging
around the benefit of IPTp was illustrated by Matthew
Chico (LSHTM, UK) from the findings of a qualitative
investigation carried out in Tanzania in 2013 into the bar-
riers to IPTp [4]. Knowledge of IPTp and an understanding
of the difference between prevention and treatment of mal-
aria among pregnant women in the study area was low.
Many women reported that SP had undesirable side ef-
fects, including the misconception that IPTp negatively
prolonged pregnancy, thereby increasing the risk to mater-
nal health at delivery. It is possible that scientific evidence
of IPTp protection against pre-term birth has been misin-
terpreted by pregnant women so that SP use in pregnancy
is viewed as something undesirable or unsafe. Such beliefs
and lack of awareness of malaria prevention interventions
have potentially significant implications on the uptake of
IPTp and should be addressed through appropriate behav-
iour change communication strategies. The same study
showed strong demand in Tanzania from national policy-
makers, district-level healthcare providers and pregnant
women at ANC facilities for holistic approaches that pro-
tect against MiP and curable sexually transmitted and re-
productive tract infections in pregnancy.
Cost-effectiveness of IPTp with SP
Findings from cost-effectiveness analyses of IPTp with
SP (IPTp-SP) were presented by Elisa Sicuri (Barcelona
Table 1 Factors affecting the effectiveness of IPTp delivery
through antenatal care platform: comparison between factors
identified through quantitative and qualitative approaches [14]
Predictors of receiving any
IPTp
Qualitative explanation
Education None
Gestation Misinterpretation of guidelines on
the lower and upper limit of the
gestational age at which SP could
be given
Reason for attending ANC If a pregnant woman is ill she first will
be attended to for that illness and she
may not receive routine ANC services
Having malaria symptoms As above, illness usually dealt with first
and IPTp should not be given
concurrently with other anti-malarial
treatment
Having the abdomen
examined and palpated
during ANC visit
None
Total amount of money
spent
SP was sometimes sold at health facilities
although it should be provided free of
charge; women spending money were
more likely to receive IPTp
None Due to fear of SP side-effects when taken
on an empty stomach, IPTp was not
given during ANC visit nor given to be
taken at home
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Fig. 2 IPTp coverage across districts in Ghana in 2003 and 2008
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Centre for International Health Research, Spain) who
showed that two doses of IPTp-SP was highly cost-
effective and that three or more doses of IPTp-SP was
more cost-effective than two doses. The first analysis es-
timated the cost-effectiveness of IPTp-SP from a ran-
domized placebo-controlled trial of IPTp-SP in the
context of ITN use and moderate SP resistance in
Mozambique [5]. This trial found that two doses of
IPTp-SP against IPTp-placebo had a protective efficacy
of 40 % (95 % Confidence Intervals [95 %CI]: 7.4; 61) for
maternal clinical malaria and 61 % (95 % CI: 7.4; 83.8)
for neonatal mortality. A threshold analysis was con-
ducted to estimate cut-off points of the main variables
beyond which IPTp-SP may no longer be cost-effective.
Even assuming a reduction in SP efficacy to 15 % in clin-
ical case management and a reduction in neonatal
deaths averted from 11 to 4.5 per 1,000 women taking
the prevention, IPTp-SP remained cost-effective. The
study concluded that two doses of IPTp-SP is a highly
cost-effective intervention both in terms of prevention
of maternal clinical malaria and reduction in neonatal
mortality in this context (Table 2). Furthermore, provision
of IPTp with a more efficacious drug than SP, even if more
expensive, may still remain a cost-effective public health
measure to prevent malaria in pregnancy, particularly in
HIV-infected pregnant women [6]. The second cost-
effectiveness study was based on the meta-analysis of IPTp
with three or more IPTp doses of SP versus two doses
across a range of African settings [7]. The meta-analysis
found that three or more doses of IPTp-SP was associated
with increased birth weight and decreased risk of low
birth weight, placental malaria and maternal parasitaemia
compared to the standard two-dose regimen. Analysis
showed that three or more doses of IPTp-SP were more
cost-effective compared to two doses of IPTp-SP. This
finding remained robust even if the underlying population
level risk of low birth weight changes or if only HIV-
negative women were considered. An update of this cost-
effectiveness analysis has since been published [8].
However, the results might not be generalizable to areas
with lower malarial transmission and/or with very high
levels of malaria parasite resistance to SP [9].
Strengthening health systems and the antenatal care
platform
Kate Mitchell (Harvard School of Public Health/Mater-
nal Health Task Force, USA) described the current shift
in the delivery of ANC. The ANC platform is a key point
of entry into the formal health system and presents a
unique opportunity to reach the majority of pregnant
women. Although ANC attendance is relatively high,
even in low income countries, further efforts need to
focus on the quality of care and service delivery. A
recent study has drawn attention to the enormous gap
between coverage as measured by attendance and cover-
age with specific ANC interventions [10]. Several recent
studies stressed other challenges with and barriers to
accessing ANC such as hidden costs (transportation,
time off work, purchase of drugs on the private market
when there were stock outs at health facilities); cultural
factors influencing timing of pregnancy disclosure and
healthcare workers negative attitudes exhibited towards
women who present at ANC facilities [11]. Findings
from a recent secondary analysis of the original focused
ANC trials showed an increase in perinatal mortality
which is of great concern and needs to be further
researched [12]. Although the original WHO-sponsored
focused ANC trial did not include sites from sub-
Saharan Africa, the WHO is working with numerous
partners to revise ANC guidelines through technical
consultations that have included mapping of ANC
guidelines worldwide and defining a new women-
centred approach to ANC delivery. Revision of ANC
guidelines will need to consider ways to increase health-
care worker adherence to delivery of IPTp and to yield
better uptake among women. This is a critical time to
revisit antenatal care policy and consider the following
issues: harmonization of policies, guidelines, and recom-
mendations; draw on lessons learned from slow IPTp
uptake; review the role of community health workers to
increase uptake of both ANC and IPTp; ensure a
women-centred approach is adopted; tap into funding
streams which support integration of maternal and new-
born health.
Beyond the ANC platform, Elaine Roman (JHPEIGO,
USA) discussed the need to target shortcomings in the
following components of the health system to improve
coverage of IPTp and key interventions: better integra-
tion of policies and guidelines between Reproductive
Health and National Control Malaria Programmes; focus
on healthcare worker capacity development both pre-
and in-service training; quality assurance through sup-
port supervision; community engagement for early ANC
Table 2 Cost-effectiveness of IPTp-SP
Intervention costs/
DALYs averted in
US$ for 2012
Intervention
Results on clinical
malaria [5]
46.02 IPTp-SP 2 doses vs
Placebo
Results on neonatal
mortality [5]
1.20 IPTp-SP 2 doses vs
Placebo
Combined analysis for
clinical malaria and
neonatal mortality [5]
1.13 IPTp-SP 2 doses vs
Placebo
Combined analysis for
clinical malaria, maternal
anaemia and low birth
weight [8]
7.28 IPTp-SP 3+ doses vs
IPTp-SP 2 doses
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attendance and IPTp uptake; ensuring availability of
commodities at ANC facilities including SP for IPTp;
monitoring and evaluation that makes use of facility-level
data for decision making; securing adequate financial
support.
Moving forward, strengthening ANC and components
of the health system that are based on specific country
contexts will be necessary to scale up IPTp coverage and
have lasting health benefit for both mother and newborn.
A summary of the key issues and recommendations for
scale-up of IPTp-SP discussed by seminar participants
following the presentations is provided below. A compre-
hensive list of recommended actions by stakeholder group
is presented in a companion paper [15].
1. What are we calling malaria-endemic countries to do?
1.1. Healthcare workers play a critical role in
making IPTp attractive to pregnant women.
There is a need to address negative healthcare-
worker attitudes and behavioural issues such as
abuse and disrespect as commonly reported by
ANC clients. The importance of healthcare
worker welfare must be considered alongside
issues such as commodities and infrastructure
needs. In low- and middle-income countries
health facilities are generally under-staffed and
healthcare workers overburdened. Motivated
healthcare workers are more likely to improve
delivery of IPTp and uptake by ANC clients.
1.2. RBM developed guidelines for behaviour
change communication (BCC) [13] which
are useful for increasing demand for and
acceptance of IPTp. Such a communication
programme should not only address knowledge
gaps but also encourage self-advocacy and ad-
dress perceived risks of malaria infection and
preventive treatment. A successful BCC strat-
egy would result in pregnant women
demanding to be protected from malaria.
1.3. Pre-service training as well as continuous medical
training focused on malaria in pregnancy and
IPTp can play a critical role in the scale up of
IPTp. This is currently done for Prevention of
Mother to Child Transmission of HIV (PMTCT)
but not uniformly for malaria in pregnancy.
1.4. The distribution of simplified guidelines on the
IPTp policy signed by local and national
authorities has proven effective at scaling up
IPTp in western Kenya.
1.5. There is a need to ensure greater integration
between different public health programmes,
not only Reproductive Health and Malaria, but
also TB and HIV so as to strike the right
balance across all activities. PMTCT is an
important part of focused ANC and has received
disproportionate attention, taking over most of
the ANC process which can overshadow other
interventions. It is also important to recognize
that HIV-positive women on prophylactic co-
trimoxazole are not eligible for IPTp with SP, and
this group represents up to a third of all pregnant
women attending ANC facilities in certain re-
gions. HIV positive pregnant women are more
susceptible to malaria than their HIV negative
counterparts and yet they receive sub-optimal
malaria prevention with co-trimoxazole. Non-
sulpha based alternative therapies are needed that
can be taken concurrently with co-trimoxazole.
1.6. Given the evidence that high-dose folic acid
(5 mg or above) counteracts SP efficacy,
countries need to ensure low-dose folic acid
(0.4 mg) is available for ANC use.
1.7. Community engagement and involvement have
demonstrated potential to raise awareness of
and to demystify challenges associated with
ANC and IPTp, and to build momentum for
early ANC attendance and IPTp uptake.
Therefore, there is a need for active community
involvement in mobilizing and educating
pregnant women about the benefits of early
ANC attendance and use of SP for prevention of
malaria during pregnancy. Active community
participation remains one of the central tenets
of primary health care, and is essential to
building strong health systems and to meeting
the healthcare needs of pregnant women.
2. What are we calling the Global Fund to do?
2.1. Although most governments in sub-Saharan
Africa have stated policies to provide ANC ser-
vices at no cost to users, the reality is that health
facilities usually function on some form of cost-
recovery basis. Therefore, pregnant women are
often expected to pay for ANC registration and/
or laboratory tests. To ensure services are indeed
free, public health budgets should cover the cost
of commodities as well as incidental expenses,
such as the cost of transport from central depots
to health facilities.
2.2. Each year during the Global Fund proposal
preparation, countries are faced with tough
decisions about which components to include in
budgets. For various reasons, the cost of
procuring SP and delivering IPTp is often
considered an in-kind expense that is to be
covered by applicants. However, there is often no
process in place to ensure these expenses are
actually met at the government level. Countries
should be encouraged to budget these costs in
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their Global Fund applications. If these costs are
not included, then there should be a strong agree-
ment in place at the national level stating that
countries will procure SP and support integration
of Reproductive Health and Malaria programmes.
3. What are we calling the researchers to do?
3.1. Develop, test and evaluate successful BCC
strategies which result in pregnant women
demanding to be protected from malaria
infection.
3.2. Evaluate the evidence on the effectiveness and
drawbacks of community distribution of IPTp.
3.3. Improve dissemination of research and lessons
learned from existing evidence.
4. What are we calling the pharmaceutical industry to do?
4.1. In some settings, the procurement of SP
has become a considerable challenge; the
pharmaceutical industry/manufacturers should
be encouraged to register SP in countries that
have IPTp policies.
4.2. Most countries are still providing high-dose folic
acid which has been shown to decrease SP effi-
cacy. The pharmaceutical industry needs to align
with ANC programmes to manufacture and to
register low-dose folic acid.
4.3. To investigate anti-malarial drugs that could re-
place SP and be given safely in the first trimester
of pregnancy.
5. What are we calling private health care providers to
do?
5.1. The importance of private healthcare providers
is often overlooked. However, their importance
in health service provision is growing in low
and middle-income countries (up to 50 % in
certain areas). Private healthcare providers, in-
cluding facilities operated by non-governmental
organizations and faith-based organizations,
should be included in IPTp training, supervi-
sion and supported with an uninterrupted sup-
ply of quality SP.
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